贾纳克斯治疗
JANX
16.51
-0.81
-4.68%
贾纳克斯治疗
US · JANX
#3187 按市值排名
上市于 2021
16.51
-0.81
-4.68%
实时 - 追踪5344个代码 - 心跳于409秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了0.1个百分点。
机构持股
- 机构持股比例
- 101.81% -0.10pp
- 机构数量
- 253 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund44.11%
Hedge Fund27.49%
VC/PE Fund22.09%
Individual/Insider5.92%
Public Company4.49%
Private Company2.17%
Insurance Company1.16%
Government Pension Fund0.30%
主要股东 截至 2026-06-30
RA Capital Management, L.P.
18.30% · 11.19M 股
BlackRock
10.03% · 6.13M 股
Prosight Management, LP
6.22% · 3.80M 股
State Street Global Advisors
4.92% · 3.00M 股
Klaus Dorner
4.91% · 3.00M 股
FMR
3.93% · 2.41M 股
Federated Hermes, Inc.
3.85% · 2.35M 股
Vanguard Capital Management, LLC
3.55% · 2.17M 股
Point72 Asset Management, L.P.
3.26% · 1.99M 股
TCG Crossover Management, LLC
2.93% · 1.79M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 38次买入 · 12次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| RA Capital Management, L.P. | -- | 18.30% |
| Sheila Gujrathi | Director | 0.18% |
| David Campbell | Chief Executive Officer | 0.18% |
| Thomas Diraimondo | Executive Director of Research & Development | 0.17% |
| Vickie Capps | Independent Director | 0.12% |
| Andy Meyer | Chief Business Officer | 0.11% |
| Charles Winter | Chief Technology Officer | 0.10% |
| Janeen Doyle | Chief Corporate & Business Development Officer | 0.06% |
| Natasha Hernday | Director | 0.01% |
| Eric Dobmeier | Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-07-30 | David Campbell | Chief Executive Officer | Other Disposition | -123,840 | -- |
| 2026-07-07 | David Campbell | Chief Executive Officer | Derivative Exercise and Retained | +7,000 | $4.21 |
| 2026-06-10 | Vickie Capps | Independent Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Vickie Capps | Independent Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-10 | Ronald Barrett | Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Ronald Barrett | Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-10 | Eric Dobmeier | Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Eric Dobmeier | Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-10 | Natasha Hernday | Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Natasha Hernday | Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-10 | Winston Kung | Independent Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Winston Kung | Independent Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-10 | Jake Simson | Independent Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Jake Simson | Independent Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-01 | Janeen Doyle | Chief Corporate & Business Development Officer | Open Market Disposition | -4,059 | $14.03 |
| 2026-05-10 | Maria Dobek | Principal Accounting Officer & VP of Accounting | Open Market Disposition | -2,038 | $14.17 |
| 2026-02-01 | William Go | Chief Medical Officer | Other Acquisition | +44,000 | -- |
| 2026-02-01 | William Go | Chief Medical Officer | Other Derivative Acquisition | +154,000 | $13.99 |
| 2026-01-01 | David Campbell | Chief Executive Officer | Other Acquisition | +96,600 | -- |
| 2026-01-01 | David Campbell | Chief Executive Officer | Open Market Disposition | -8,072 | $13.73 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
贾纳克斯治疗 讨论区 0 条评论